Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension İdiyopatik intrakraniyal hipertansiyon relaps tedavisi sırasında metabolik asidoz

Güngör Tunçer Ö., Nalbantoğlu M., Şengül E. A., BAYKAL B.

Agri, vol.35, no.2, pp.107-110, 2023 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 2
  • Publication Date: 2023
  • Doi Number: 10.14744/agri.2021.05025
  • Journal Name: Agri
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.107-110
  • Keywords: Acetazolamide, intracranial hypertension, metabolic acidosis, papilledema, SARS-CoV-2 pandemic
  • Istanbul University Affiliated: Yes


We herein present a 40-year-old female physician who was diagnosed with idiopathic intracranial hypertension (IIH) 4 years ago. In the last years, the patient was in remission without any medications. Since the onset of COVID-19 pandemic, she has been stressfully working in the high-risk area, therefore using personal protective equipment (N95 mask, protective clothing, goggles, and protective cap) during the day for extended periods. Her headaches recurred and the patient was diagnosed with a relapse of IIH; acetazolamide and afterward topiramate were initiated, with diet treatment. Symptomatic metabolic acidosis, which is otherwise a rare side effect of the IIH treatment and not seen in her first attack even with higher doses, developed during the follow-up, presenting with shortness of breath and chest tightening. The emerging problems of IIH diagnosis and management during the COVID-19 pandemic will be discussed.